Payment overview · 2025
General Payments
$1,252.08
57 reported records · 20 companies
Healthcare provider profile · identity verified
William Keith Harris, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, MS · NPI 1902874571
Verified facts
What the public records show
CMS Open Payments records show William Keith Harris, MD received $1,252.08 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $310.15 | 24.8% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $242.44 | 19.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $127.06 | 10.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.95 | 4.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.81 | 4.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.31 | 4.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.99 | 4.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.52 | 4.0% | 3 | 2025 |
| Artivion, Inc. | Unresolved — no canonical attribution shown | $48.60 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.58 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.16 | 3.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.69 | 1.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.40 | 1.7% | 1 | 2025 |
| ALON MEDICAL TECHNOLOGY | Unresolved — no canonical attribution shown | $21.30 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.26 | 1.5% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.97 | 1.4% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $16.75 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.22 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.46 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,252.08 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $202.09 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $202.09 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $202.09 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $129.93 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.21 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.23 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.41 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.95 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $57.95 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $57.81 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.99 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.99 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| AMDS-Ascyrus Medical Normalized: amds ascyrus medical |
Device | Artivion, Inc. | $48.60 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.58 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.35 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 160 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 151 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
151 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1109 | 304 |
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 223 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 713 | 207 |
| Gabapentin | Gabapentin | 691 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 673 | 151 |
| Metformin Hcl | Metformin Hcl | 561 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 550 | 154 |
| Lisinopril | Lisinopril | 494 | 135 |
| Omeprazole | Omeprazole | 473 | 123 |
| Hydrochlorothiazide | Hydrochlorothiazide | 468 | 125 |
| Alprazolam | Alprazolam | 462 | 73 |
| Lovastatin | Lovastatin | 438 | 118 |
| Losartan Potassium | Losartan Potassium | 429 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 96 |
| Tizanidine Hcl | Tizanidine Hcl | 349 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 342 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 338 | 98 |
| Meloxicam | Meloxicam | 315 | 105 |
| Duloxetine Hcl | Duloxetine Hcl | 313 | 76 |
| Potassium Chloride | Potassium Chloride | 313 | 85 |
| Glimepiride | Glimepiride | 296 | 82 |
| Sertraline Hcl | Sertraline Hcl | 287 | 71 |
| Famotidine | Famotidine | 276 | 82 |
| Trazodone Hcl | Trazodone Hcl | 267 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 68 |
| Furosemide | Furosemide | 252 | 74 |
| Metformin Hcl Er | Metformin Hcl | 227 | 64 |
| Allopurinol | Allopurinol | 223 | 53 |
| Tramadol Hcl | Tramadol Hcl | 216 | 52 |
| Valsartan | Valsartan | 198 | 45 |
| Ezetimibe | Ezetimibe | 193 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 181 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 54 |
| Simvastatin | Simvastatin | 174 | 48 |
| Carvedilol | Carvedilol | 166 | 49 |
| Eliquis | Apixaban | 160 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 24 |
| Mounjaro | Tirzepatide | 151 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 149 | 41 |
| Methocarbamol | Methocarbamol | 148 | 47 |
| Montelukast Sodium | Montelukast Sodium | 142 | 39 |
| Ozempic | Semaglutide | 138 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 35 |
| Prednisone | Prednisone | 129 | 108 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 96 |
| Synthroid | Levothyroxine Sodium | 120 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 98 | 21 |
| Nifedipine Er | Nifedipine | 96 | 21 |
| Warfarin Sodium | Warfarin Sodium | 95 | 22 |
| Mirtazapine | Mirtazapine | 92 | 19 |
| Clonazepam | Clonazepam | 91 | 17 |
| Atenolol | Atenolol | 89 | 25 |
| Donepezil Hcl | Donepezil Hcl | 87 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 24 |
| Naproxen | Naproxen | 86 | 33 |
| Cefuroxime | Cefuroxime Axetil | 85 | 76 |
| Lorazepam | Lorazepam | 85 | 24 |
| Alendronate Sodium | Alendronate Sodium | 84 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 76 | 48 |
| Azithromycin | Azithromycin | 74 | 64 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 53 |
| Felodipine Er | Felodipine | 72 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 14 |
| Spironolactone | Spironolactone | 71 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 21 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 70 | 20 |
| Cefdinir | Cefdinir | 67 | 53 |
| Benazepril Hcl | Benazepril Hcl | 65 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 12 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Jardiance | Empagliflozin | 59 | 13 |
| Pregabalin | Pregabalin | 57 | 15 |
| Meclizine Hcl | Meclizine Hcl | 55 | 23 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 12 |
| Chlorthalidone | Chlorthalidone | 53 | 17 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 33 |
| Valacyclovir | Valacyclovir Hcl | 47 | 27 |
| Diazepam | Diazepam | 46 | 11 |
| Fluconazole | Fluconazole | 46 | 28 |
| Amoxicillin | Amoxicillin | 42 | 28 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Linzess | Linaclotide | 42 | 14 |
| Propranolol Hcl | Propranolol Hcl | 42 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Temazepam | Temazepam | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 23 |
| Promethazine Hcl | Promethazine Hcl | 38 | 13 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 14 |
| Mupirocin | Mupirocin | 33 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 24 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 11 |
| Cephalexin | Cephalexin | 25 | 23 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 23 | 14 |
| Nitroglycerin | Nitroglycerin | 23 | 13 |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 14 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 12 |
| Novolog | Insulin Aspart | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Topiramate | Topiramate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,252.08 · 57 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMDS-Ascyrus Medical, AREXVY, ATRICLIP LAA EXCLUSION SYSTEM, Auvelity, BOOSTRIX, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FREESTYLE LIBRE, GEMTESA, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error